MedTrace Logo

Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injury

NCT06622239 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-05-22

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if naltrexone works to treat nonsuicidal self-injurious behavior in adolescents and adults.

Conditions

  • Nonsuicidal Self-Injury

Interventions

DRUG

Naltrexone

naltrexone 50mg for 6 weeks

DRUG

Placebo

placebo for 6 weeks

Sponsors & Collaborators

  • Whanin Pharmaceutical Company

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Yong Min Ahn, M.D, Ph.D · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-02-28
Completion
2027-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06622239 on ClinicalTrials.gov